Back to companies

Hikma Pharmaceuticals Plc: Overview

Want to continue viewing company data?

Sign up for exclusive competitive intelligence.
Company Data Subscription $329 per month (billed Annually)
Signup to View Free Sample

Hikma Pharmaceuticals Plc (Hikma) develops, manufactures and markets branded and non-branded generics and in-licensed products. The company specializes in the areas of cardiovascular, diabetes, central nervous system (CNS), cancer, dermatology, genitourinary system, hormones and respiratory system, among others. It offers generics in various dosage forms including tablets, capsules, solutions and suspensions. Hikma Pharmaceuticals sells its products through sales and marketing teams and representatives to leading wholesalers, pharmacy chains, governments and hospital purchasing organizations. The company markets its products in the UK, the Middle East, and North Africa (MENA) and Europe and rest of the world. Hikma Pharmaceuticals is headquartered in London, the UK.

Headquarters United Kingdom

Address 1 New Burlington Place, London, W1S2HR


Telephone 44 20 73992760

No of Employees 8,703

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange HIK (LON)

Revenue (2021) $2.6B 9.1% (2021 vs 2020)

EPS XXX

Net Income (2021) XXX -2.3% (2021 vs 2020)

Market Cap* $4.1B

Net Profit Margin (2021) XXX -10.4% (2021 vs 2020)

* As of and is in US$

Explore premium data & analytics

440+

Marketed Drugs

Understand Hikma Pharmaceuticals Plc’s commercialized product portfolio to stay one step ahead of the market.

140+

Clinical Trials

Determine Hikma Pharmaceuticals Plc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

30+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Hikma Pharmaceuticals Plc’s relevant decision makers and contact details.

12+

Catalyst Calendar

Proactively evaluate Hikma Pharmaceuticals Plc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

7

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

4

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

3

Pipeline Drugs

Identify which of Hikma Pharmaceuticals Plc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

3

Medical Pipeline Products

A database of medical devices that are in the process to get approved for sale around the world. Devices that are in development, through to those in the approval process are included.

3

Medical Clinical Trials

A database of clinical trials planned, currently ongoing, completed, suspended, withdrawn, and terminated in countries around the world.

2

Medical Marketed Products

A database of medical devices currently for sale around the world. Devices that have been approved by a regulatory authority are included.

Subscribe to Company Analytics & gain access to premium industry data & analytics Subscribe to Company Analytics & gain access to premium industry data & analytics Start Here

Products and Services

Products Brands
Injectables: Amoclan
Fentanyl Blopress
Glycopyrrolate Cresemba
XXX XXX
XXX XXX
XXX XXX
Subscribe to Company Analytics for access to more products & services data Subscribe to Company Analytics for access to more products & services data Learn More

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2022 Contracts/Agreements In April, the company entered into a commercialisation and license agreement for OPNT003, Nasal Nalmefene, in Europe and the UK.
2022 Acquisitions/Mergers/Takeovers In April, the company acquired the US-based Custopharm from Water Street Healthcare Partners for US$425 million.
2022 Contracts/Agreements In January, the company entered into an agreement to acquire the Canadian assets of Teligent Inc. for US$45.75 million.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Get Started
Image for loader

Competitor Comparison

Key Parameters Hikma Pharmaceuticals Plc Johnson & Johnson Pfizer Inc F. Hoffmann-La Roche Ltd Novartis AG
Headquarters United Kingdom United States of America United States of America Switzerland Switzerland
City London New Brunswick New York Basel Basel
State/Province - New Jersey New York - -
No. of Employees 8,703 141,700 79,000 100,920 110,000
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more

Key Financial Charts

Operating Margin
Operating Margin
EPS (Earnings per Share)
EPS (Earnings per Share)
Debt to Equity Ratio
Debt to Equity Ratio
Return on Assets
Return on Assets
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Said Darwazah Chairman; Chief Executive Officer Executive Board 2022 -
Khalid Nabilsi Chief Financial Officer Senior Management 2011 -
Shahin Fesharaki Chief Scientific Officer Senior Management 2019 -
Hussein Arkhagha Chief - Counsel Senior Management 2020 -
Mazen Darwazah President - MENA; Executive Vice Chairman Executive Board 2014 63
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Gain more insight into company management & employee structure with Company Analytics Gain more insight into company management & employee structure with Company Analytics Subscribe
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer